475P - Clinical characteristics and current management of non-small cell lung cancer patients aged more than 65 years old in Thailand: A single institute...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Geriatric Oncology
Non-Small-Cell Lung Cancer, Metastatic
Presenter NATTAYA Sintawichai
Citation Annals of Oncology (2016) 27 (suppl_9): ix139-ix156. 10.1093/annonc/mdw594
Authors N. Sintawichai1, A. Petchlorlian2, S. Sakdejayont1, A. Chewcharat3, S. Tanasanvimon1, N. Parinyanitikul1
  • 1Medical Oncology, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH
  • 2Medical Geriatric, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH
  • 3Faculty Of Medicine, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH



Non-small cell lung cancer (NSCLC) is the most important cause of cancer mortality worldwide. Similar in Thailand, incidence of lung cancer is high with increasing trend among elderly patients. Diagnosis and treatment of lung cancer in elderly patients who may have multiple co-morbidities and declined organ function is challenging. Moreover, systematic data collection in our institute remains unknown. The aim of this study is to describe basic clinical data and evaluate current practice in diagnostic and treatment of this special population in order to achieve the superior standard of care.


One hundred and sixteen patients who were diagnosed with NSCLC at aged more than 65 years at King Chulalongkorn Memorial Hospital between January 2014 and 31 December 2015 were reviewed retrospectively. Clinical characteristics, treatment modalities and survival outcomes were also analyzed.


In initial analysis among 50 patients with advanced NSCLC, the mean age of diagnosis was 74.64 years (65-87). Most patients were non-smoker (95.65%). Majority of histopathology was adenocarcinoma (95.56%). Tissue diagnosis could be accomplished in almost patients (41 out of 50) with biopsy and cytology. Only 19 out of 50 (38%) received systemic treatment but the rest did not receive any treatment due to poor performance status and loss to follow-up. 12 out of 19 (63%) received platinum-based doublet chemotherapy, 3 out of 19 (15.7%) received single agent chemotherapy and 4 out of 19 (21%) received EGFR-TKI as first-line treatment. Among 15 patients who received chemotherapy, mean relative dose intensity was 84.25% and mean cycle of treatment was 3.73 cycles (1-6). Overall survival and progression-free survival will be further analyzed.


Accomplishment and feasibility of systemic treatment in advanced NSCLC in elderly remain the challenging issue which is leading to patient’s outcome. Systematic data collection and further clinical study in such a special population group are still needed.

Clinical trial indentification

Legal entity responsible for the study

King Chulalongkorn Memorial Hospital


King Chulalongkorn Memorial Hospital


All authors have declared no conflicts of interest.